SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Fishman, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoenfeld, Y.
Right arrow Articles by Fishman, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Role of IL-3 in the Antiphospholipid Syndrome

Yehuda Shoenfeld

Research Unit of Autoimmune Diseases, Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Research Institute, Golda Medical Center (Hasharon Hospital), Petach-Tikva, Affiliated to Bar-Ilan University, Israel

Pnina Fishman

Research Unit of Autoimmune Diseases, Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Research Institute, Golda Medical Center (Hasharon Hospital), Petach-Tikva, Affiliated to Bar-Ilan University, Israel

Antiphospholipid syndrome (APLS) is characterized by recurrent thromboembolic phenomena, thrombocytopenia and fetal loss. We describe various methods of induction of experimental APLS. These models were employed to study a variety of therapeutic agents including low dose aspirin, low molecular weight heparin, IVIG and thromboxane receptor antagonist. Because interleukin-3 (IL-3) is a multilineage cytokine affecting also megakaryocytes, is regarded as a 'good' cytokine in various stages of pregnancy and as low levels of IL-3 were recorded in APLS, it was logical to employ IL-3 as a therapy for APLS. Indeed, this treatment completely abrogated all the manifestations of experimental APLS. Furthermore, it was found that low dose aspirin most probably affect positively APLS via inducing an increased production of IL-3 by monocytes.

Key Words: Cytokines • Interleukin-3 • Autoimmunity • Antiphospholipid syndrome

Lupus, Vol. 3, No. 4, 259-261 (1994)
DOI: 10.1177/096120339400300410
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 LupusHome page
M.D. Lockshin
Review : Pregnancy loss and antiphospholipid antibodies
Lupus, January 1, 1998; 7(2_suppl): S86 - S89.
[Abstract] [PDF]


Advertisement